Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
MAP3K15 ASK3
Sequence Length (AA) Molecular Weight (Da)
1313 147437
Protein Name
Mitogen-activated protein kinase kinase kinase 15
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MESGGGNAPA GALGAASESP QCPPPPGVEG AAGPAEPDGA AEGAAGGSGE
60 70 80 90 100
GESGGGPRRA LRAVYVRSES SQGGAAGGPE AGARQCLLRA CEAEGAHLTS
110 120 130 140 150
VPFGELDFGE TAVLDAFYDA DVAVVDMSDV SRQPSLFYHL GVRESFDMAN
160 170 180 190 200
NVILYHDTDA DTALSLKDMV TQKNTASSGN YYFIPYIVTP CADYFCCESD
210 220 230 240 250
AQRRASEYMQ PNWDNILGPL CMPLVDRFIS LLKDIHVTSC VYYKETLLND
260 270 280 290 300
IRKAREKYQG EELAKELARI KLRMDNTEVL TSDIIINLLL SYRDIQDYDA
310 320 330 340 350
MVKLVETLEM LPTCDLADQH NIKFHYAFAL NRRNSTGDRE KALQIMLQVL
360 370 380 390 400
QSCDHPGPDM FCLCGRIYKD IFLDSDCKDD TSRDSAIEWY RKGFELQSSL
410 420 430 440 450
YSGINLAVLL IVAGQQFETS LELRKIGVRL NSLLGRKGSL EKMNNYWDVG
460 470 480 490 500
QFFSVSMLAH DVGKAVQAAE RLFKLKPPVW YLRSLVQNLL LIRRFKKTII
510 520 530 540 550
EHSPRQERLN FWLDIIFEAT NEVTNGLRFP VLVIEPTKVY QPSYVSINNE
560 570 580 590 600
AEERTVSLWH VSPTEMKQMH EWNFTASSIK GISLSKFDER CCFLYVHDNS
610 620 630 640 650
DDFQIYFSTE EQCSRFFSLV KEMITNTAGS TVELEGETDG DTLEYEYDHD
660 670 680 690 700
ANGERVVLGK GTYGIVYAGR DLSNQVRIAI KEIPERDSRY SQPLHEEIAL
710 720 730 740 750
HKYLKHRNIV QYLGSVSENG YIKIFMEQVP GGSLSALLRS KWGPMKEPTI
760 770 780 790 800
KFYTKQILEG LKYLHENQIV HRDIKGDNVL VNTYSGVVKI SDFGTSKRLA
810 820 830 840 850
GVNPCTETFT GTLQYMAPEI IDQGPRGYGA PADIWSLGCT IIEMATSKPP
860 870 880 890 900
FHELGEPQAA MFKVGMFKIH PEIPEALSAE ARAFILSCFE PDPHKRATTA
910 920 930 940 950
ELLREGFLRQ VNKGKKNRIA FKPSEGPRGV VLALPTQGEP MATSSSEHGS
960 970 980 990 1000
VSPDSDAQPD ALFERTRAPR HHLGHLLSVP DESSALEDRG LASSPEDRDQ
1010 1020 1030 1040 1050
GLFLLRKDSE RRAILYKILW EEQNQVASNL QECVAQSSEE LHLSVGHIKQ
1060 1070 1080 1090 1100
IIGILRDFIR SPEHRVMATT ISKLKVDLDF DSSSISQIHL VLFGFQDAVN
1110 1120 1130 1140 1150
KILRNHLIRP HWMFAMDNII RRAVQAAVTI LIPELRAHFE PTCETEGVDK
1160 1170 1180 1190 1200
DMDEAEEGYP PATGPGQEAQ PHQQHLSLQL GELRQETNRL LEHLVEKERE
1210 1220 1230 1240 1250
YQNLLRQTLE QKTQELYHLQ LKLKSNCITE NPAGPYGQRT DKELIDWLRL
1260 1270 1280 1290 1300
QGADAKTIEK IVEEGYTLSD ILNEITKEDL RYLRLRGGLL CRLWSAVSQY
1310 1313
RRAQEASETK DKA

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-841 Collapse assay details

Data source: Panorama

Official Gene Symbol
MAP3K15
Peptide Sequence
ETLLNDIR
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
245
Peptide End
252
CPTAC ID
CPTAC-841
Peptide Molecular Mass
972.5240
Species
Homo sapiens (Human)
Assay Type
Direct PRM
Matrix
Pooled patient derived xenograft breast tumor digest
Submitting Laboratory
Washington University in St. Louis
Submitting Lab PI
Reid Townsend

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
TripleTOF 5600+ (SCIEX)
Internal Standard
Peptide
Peptide Standard Purity
Crude
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
2DPlus nano-LC (Eksigent)
Column Packing
ChromXP C18-CL, 3 µm, 120 Å
Column Dimensions
200 µm x 15 cm
Flow Rate
800 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y3 (1+) 15.6 6.1 5.9 15 6.8 9.9 21.6 9.1 11.5 15 15 15
y4 (1+) 3.7 3.5 3.2 4.9 2.8 3.1 6.1 4.5 4.5 15 15 15
y5 (1+) 5.3 3.5 3.8 4.8 3.5 4.5 7.2 4.9 5.9 15 15 15
y6 (1+) 8.5 4.8 3.8 7.4 4.4 5.1 11.3 6.5 6.4 15 15 15
sum 2.2 1.9 1.4 2.3 1.7 2.9 3.2 2.5 3.2 15 15 15


Additional Resources and Comments


Assay Details for CPTAC-842 Collapse assay details

Data source: Panorama

Official Gene Symbol
MAP3K15
Peptide Sequence
IGVRLNSLLGR
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
N/A
Peptide Start
426
Peptide End
436
CPTAC ID
CPTAC-842
Peptide Molecular Mass
1,196.7353
Species
Homo sapiens (Human)
Assay Type
Direct PRM
Matrix
Pooled patient derived xenograft breast tumor digest
Submitting Laboratory
Washington University in St. Louis
Submitting Lab PI
Reid Townsend

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
TripleTOF 5600+ (SCIEX)
Internal Standard
Peptide
Peptide Standard Purity
Crude
Peptide Standard Label Type
13C and 15N at C-terminus R
LC
2DPlus nano-LC (Eksigent)
Column Packing
ChromXP C18-CL, 3 µm, 120 Å
Column Dimensions
200 µm x 15 cm
Flow Rate
800 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y3 (1+) 7.8 5.1 3.6 7.5 7.2 4.6 10.8 8.8 5.8 15 15 15
y4 (1+) 14.3 9.4 6.5 13.7 8.2 7.4 19.8 12.5 9.8 15 15 15
y5 (1+) 12.7 9.7 5.8 13 9 5.9 18.2 13.2 8.3 15 15 15
y6 (1+) 9.7 7.4 3.5 12 7.6 5.9 15.4 10.6 6.9 15 15 15
y7 (1+) 11.3 7.4 5.8 11.5 8.1 7.5 16.1 11 9.5 15 15 15
b8 (1+) 20.3 8 10.6 21 10.1 13.5 29.2 12.9 17.2 15 15 15
b7 (1+) 9.3 6.9 3.9 9.1 7.7 5.6 13 10.3 6.8 15 15 15
b6 (1+) 17.1 13.2 7.8 21.2 17.9 8.5 27.2 22.2 11.5 15 15 15
b4 (1+) 13.3 13 12.4 20.2 13.1 13 24.2 18.5 18 15 15 15
sum 4.1 2.1 2 3.5 4 3.4 5.4 4.5 3.9 15 15 15


Additional Resources and Comments